Lab Literacy / Reading Your IGF-1 Result Like a Researcher
9 min readAmong every blood test associated with peptide research, one stands apart: IGF-1.
It is the only marker in this space that researchers use to directly drive dosing decisions. Not as a safety check. Not as a monitoring endpoint. As the number that determines whether the dose goes up, stays the same, or comes down. No other lab value in peptide research has that role.
The reason is structural. IGF-1 is the direct readout of growth hormone activity — not a surrogate, not a downstream effect, but the hormone that GH stimulates the liver to produce. When a GH-axis peptide (tesamorelin, CJC-1295, ipamorelin, MK-677) does what it is supposed to do, IGF-1 moves. When it does not, IGF-1 does not move. That makes it the clearest signal available.
But reading an IGF-1 result is not as simple as checking whether it falls inside a printed range. The number has to be interpreted against age, sex, and a statistical concept called a Z-score. Here is how researchers do it.
IGF-1 changes dramatically over a lifetime. It rises through childhood and adolescence, peaks in the twenties, and then declines steadily. A level that is perfectly normal for a 60-year-old would be conspicuously low for a 25-year-old. That is why a single reference range on a lab report is misleading — it has to be adjusted for the person standing in front of it.
The age-stratified ranges from the primary IGF-1 reference (Bidlingmaier 2014, Journal of Clinical Endocrinology & Metabolism) give the picture:
| Age range | Approximate IGF-1 range (ng/mL) |
|---|---|
| 25-39 years | ~114 - 492 |
| 40-54 years | ~90 - 360 |
| 55+ years | ~71 - 290 |
The overlap between the bottom of the youngest band and the top of the oldest band is almost none. A 30-year-old with an IGF-1 of 80 ng/mL is well below their age-matched range. A 60-year-old with that same 80 ng/mL is sitting near the middle of theirs. Same number, completely different interpretation.
This is the first thing to check when you see an IGF-1 result: what are the age- and sex-adjusted reference ranges for this person? If the lab report does not provide them — and many do not — the raw number is close to useless.
Reference ranges tell you whether a value is "normal," but they do not tell you how far from normal it is, or in which direction. That is what a Z-score does.
A Z-score expresses how many standard deviations a result sits from the age- and sex-matched mean. Zero means dead average. +2 means two standard deviations above the mean — roughly the 97th percentile. -2 means two standard deviations below — roughly the 3rd percentile.
| Z-score | Interpretation |
|---|---|
| -2 to +2 | Normal range |
| Below -2 | Low for age — the pattern GH-secretagogue research targets |
| Above +2 | High for age — raises safety concerns |
The normal window of -2 to +2 captures roughly 95% of the healthy population. Below -2 is where researchers look when they are studying GH-axis interventions — because that is where the intervention has a clear rationale. The Nass 2008 MK-677 trial, for example, enrolled elderly adults with a mean baseline IGF-1 of 141 mcg/L, which is low for that age group. The entire trial was built around people whose IGF-1 sat in that below-normal band.
Above +2 is where the safety concern lives. If a GH-axis peptide pushes IGF-1 above the age-adjusted normal range, the dose comes down. There is no scenario in the published guidelines where the target is above normal.
The Endocrine Society's 2011 clinical practice guideline and the 2019 AACE update both state the same target for GH replacement therapy: titrate the dose until IGF-1 reaches the upper portion of the age- and sex-adjusted normal range. Not above it. Not at the population mean. At the top of normal.
The reasoning is straightforward. Growth hormone deficiency means IGF-1 is low. Replacement means bringing it back up. The question is: how far up?
The guidelines chose the upper end of normal because that is where the deficiency symptoms resolve for most patients — improved body composition, energy, bone density — while staying within the range that the body's own regulatory systems are designed to handle. IGF-1 above the normal range is associated with acromegaly-like changes: joint pain, insulin resistance, organ enlargement. The whole point of measuring IGF-1 during titration is to get the benefit without crossing into that territory.
The titration process itself is disciplined:
This is the only major peptide class where a lab result directly drives the dose. GLP-1 agonists use a fixed q4-week titration schedule regardless of lab values — the dose escalates on a calendar, not a blood test. Tesamorelin is a fixed 2 mg/day with no titration at all. GH-axis therapy is different: the IGF-1 number is the steering wheel.
The Nass 2008 trial of MK-677 (published in the Journal of Clinical Endocrinology & Metabolism) is one of the longest-running studies of an oral GH secretagogue, and its IGF-1 data illustrates how the age-curve concept plays out in practice.
The trial enrolled adults aged 65 and older — a population where IGF-1 is naturally declining. The mean baseline IGF-1 was 141 mcg/L, which is low for that age group. After two years of 25 mg/day oral MK-677, the mean rose to 219 mcg/L.
That increase moved participants from the low end toward the middle of their age-matched range. It did not push them above it. And over those two years, fasting glucose went up modestly — expected with any GH-axis intervention — but no participant developed diabetes. That combination is meaningful: IGF-1 moved in the intended direction without the glucose escalation crossing a clinical threshold.
The study did not titrate the dose based on IGF-1 (it was a fixed 25 mg/day), but it measured IGF-1 throughout precisely because that is the marker that tells you whether a GH-axis intervention is biologically active. The body-composition results — DEXA-measured fat-free mass changes — were interpreted in the context of those IGF-1 values. The two are linked: the IGF-1 tells you the intervention reached its target; the DEXA tells you whether reaching that target produced the desired tissue-level effect.
Mistake one: treating the lab-report range as sufficient. Most lab reports print a single reference range — something like 81-267 ng/mL — without age or sex adjustment. If you are 30 years old and your IGF-1 is 120 ng/mL, that single-range report might show it as "normal." Against the age-adjusted range for a 30-year-old (~114-492), 120 is at the very bottom. Against the range for a 60-year-old (~71-290), it looks fine. Same number, opposite conclusions. The age-adjusted range is what matters.
Mistake two: assuming higher is better. The dose-response relationship for GH-axis peptides is not "more IGF-1 equals more benefit." It is a curve that bends: benefit increases as IGF-1 rises from deficient toward normal, then flattens, then the risk profile deteriorates if it keeps rising past the age-adjusted ceiling. Guidelines target the top of normal precisely because that is where the benefit-to-risk ratio is favorable. Above that line, you are adding risk without adding benefit.
When a peptide study reports IGF-1 values, three questions tell you most of what you need to know:
IGF-1 is the most informative single marker in peptide research, and it is also the one most often misread. The age curve and the Z-score are not optional refinements. They are the difference between a number that means something and a number that does not.
This article is for educational purposes and is not medical advice. It describes how published clinical trials and clinical guidelines interpret IGF-1. It does not recommend any test, peptide, or protocol. Decisions about testing or treatment belong with a qualified clinician who knows your medical history.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.